Track topics on Twitter Track topics that are important to you
Ergomed Plc (LON:ERGO), the drug development and pharma services company, has brought forward the reporting date for top-line results for its phase-IIb trial of a potential blockbuster blood thickening agent. Having reached the recruitment mid-point for coagulant PeproStat, it expects to deliver the first data from the study by the fourth-quarter of this year, rather than in the first three months of 2018. "The accelerated recruitment of this phase-IIb trial demonstrates not only strong physician interest in this innovative haemostat but also Ergomed's ability as a specialist drug developer to efficiently recruit patients and conduct studies faster than industry standards,” said chief executive, Dr Miroslav Reljanovic. Big market The company reckons the thickening agent, which is used to staunch bleeding during surgery, has the potential to tap into a market worth US$2.1bn. PeproStat, based on a synthetic peptide which eliminates the risk of exposure to blood-derived materials, is more stable than existing products and has a fast mode of action. “With these advantages Ergomed expects the product will gain significant market share,” the company said. READ: Our Big Picture overview of Ergomed
Original Article: Ergomed trial of blood thickener on the fast-trackNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...